Third installation of Elekta’s high-field MR-guided linear accelerator underway at University Medical Centre Utrecht

Reinforces commitment to research exploring how real-time clinical imaging
coupled with precision radiotherapy can improve patient outcomes
STOCKHOLM, May 26, 2016 – Elekta (EKTA-B.ST) and Royal Philips (NYSE:PHG,
AEX:PHIA) today announced the installation of a third high-field (1.5 Tesla) MR
-guided linear accelerator (MR-linac) system at University Medical Centre (UMC)
Utrecht. The Elekta MR-linac is designed to capture high-quality images of
tumors and surrounding tissue, allowing physicians to rapidly assess and respond
by modifying the radiation treatment, a responsive intervention approach.

“UMC Utrecht has been a leading proponent of the power of MR-linac technology to
transform radiotherapy, and we are excited to announce expanded capabilities
through installation of a third system,” said Bas Raaymakers, PhD, Professor of
experimental clinical physics in the Department of Radiotherapy at UMC Utrecht.
“The ability to visualize radiation therapy during treatment and to adapt
treatment in real time based on detailed MR images would allow us to treat
cancer with unprecedented levels of precision and accuracy, while improving
efficacy and reducing side effects. Just as surgeons require a clear view of the
surgical field, and often require sophisticated imaging equipment, radiation
oncologists need a 21st century approach to visualize and adapt the radiotherapy
field to achieve optimum outcomes for patients.”

UMC Utrecht is the founding member of Elekta’s MR-linac consortium, established
in 2012 by Elekta and technology partner Philips. The consortium partners are
committed to demonstrating that combining high-field MR imaging with image
guided radiotherapy will elevate the standard of care for the most prominent
cancers that account for more than half of cancer mortality worldwide as well as
less prevalent cancers that are currently not well controlled.

“We are extremely pleased with the rapid progress made to date in installing
high-field MR-linac systems worldwide,” said Tomas Puusepp, President and CEO of
Elekta. “UMC Utrecht is a leading global oncology center and has been
instrumental in making this leading-edge technology platform a reality. We are
grateful to all of our MR-linac consortium collaborators for their efforts to
improve the current paradigm of image guided radiotherapy and commitment to
addressing unmet clinical needs.”

“After the significant technology hurdles that the teams have successfully
overcome in order to combine advanced high-field digital magnetic resonance
imaging with a state-of-the-art linear accelerator, and then validate and test
the system, we are now about to enter the next phase of our important journey,”
said Rob Cascella, CEO Diagnosis and Treatment at Philips. “I am convinced that
the combined technology and clinical expertise of Philips, Elekta, UMC Utrecht
and the other consortium partners will enable us to demonstrate the tremendous
potential of MR-guided radiation therapy in clinical oncology.”

In 2009 UMC Utrecht showed the first ‘proof of principle’ testing with an
experimental MR-linac system. In 2014 the UMC Utrecht installed a high-field MR
-linac and has since been conducting functional testing in a non-clinical
capacity. The new system will be used for further non-clinical studies, but it
may also be ultimately used for clinical treatments.

About MR-linac
Elekta’s MR-linac integrates a state-of-the-art radiotherapy system and a high
-field MRI scanner with sophisticated software that allows a physician to
clearly see the patient’s anatomy in real time. The MR-linac is designed to
improve targeting of tumor tissue while reducing exposure of normal tissue to
radiation beams. It will allow physicians to precisely locate a tumor, as well
as lock onto it during delivery, even when tumor tissue is moving during
treatment or changes shape, location or size between treatment sessions.

Elekta’s MR-linac is a work in progress and not available for sale or
distribution.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time

Steve Klink, Philips Group Communications
Tel: +31 610 888 824, e-mail: steve.klink@philips.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on May 26, 2016.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people’s health and enabling better outcomes across the
health continuum from healthy living and prevention, to diagnosis, treatment and
home care. Philips leverages advanced technology and deep clinical and consumer
insights to deliver integrated solutions. The company is a leader in diagnostic
imaging, image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips’ wholly owned subsidiary
Philips Lighting is the global leader in lighting products, systems and
services. Headquartered in the Netherlands, Philips posted 2015 sales of EUR
24.2 billion and employs approximately 104,000 employees with sales and services
in more than 100 countries. News about Philips can be found at
www.philips.com/newscenter.